Lyell Wealth Management LP Sells 10,508 Shares of iShares Biotechnology ETF $IBB

Lyell Wealth Management LP cut its stake in iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 64.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,774 shares of the financial services provider’s stock after selling 10,508 shares during the quarter. Lyell Wealth Management LP’s holdings in iShares Biotechnology ETF were worth $730,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IBB. Signet Financial Management LLC grew its position in iShares Biotechnology ETF by 3.3% during the 2nd quarter. Signet Financial Management LLC now owns 2,579 shares of the financial services provider’s stock valued at $326,000 after purchasing an additional 83 shares during the last quarter. Apollon Wealth Management LLC lifted its stake in shares of iShares Biotechnology ETF by 1.1% in the 1st quarter. Apollon Wealth Management LLC now owns 8,754 shares of the financial services provider’s stock worth $1,120,000 after purchasing an additional 96 shares during the period. SBI Securities Co. Ltd. raised its stake in iShares Biotechnology ETF by 5.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 2,198 shares of the financial services provider’s stock worth $281,000 after acquiring an additional 108 shares during the period. KFG Wealth Management LLC raised its stake in iShares Biotechnology ETF by 4.8% during the 2nd quarter. KFG Wealth Management LLC now owns 2,444 shares of the financial services provider’s stock worth $309,000 after acquiring an additional 112 shares during the period. Finally, QRG Capital Management Inc. grew its holdings in iShares Biotechnology ETF by 5.3% during the 2nd quarter. QRG Capital Management Inc. now owns 2,437 shares of the financial services provider’s stock valued at $308,000 after buying an additional 123 shares in the last quarter. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Up 1.5%

Shares of IBB opened at $156.49 on Tuesday. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $157.01. The company has a 50 day simple moving average of $143.43 and a two-hundred day simple moving average of $131.77.

iShares Biotechnology ETF Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were paid a dividend of $0.0828 per share. This represents a $0.33 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend was Tuesday, September 16th.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.